A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities
More details
Hide details
Changi General Hospital, Singapore
Submission date: 2016-08-09
Final revision date: 2016-09-24
Acceptance date: 2016-10-14
Publication date: 2016-10-14
Corresponding author
Phaik Yuan Poh   

Changi General Hospital, 2, Simei Street 3, 529889 Singapore
Tob. Prev. Cessation 2016;2(October):76
Smoking cessation clinic (SCC) was introduced into Singapore’s healthcare setting to combat the increase in smoking prevalence. This study aims to determine (1)the effectiveness of a pharmacist-managed SCC, and (2)the association between abstinence rates and different treatment modalities, in Changi General Hospital.

445 patients who had attended the SCC were retrospectively reviewed. These patients received structured smoking cessation counselling with or without additional cessation aid comprising of nicotine replacement therapy (NRT), varenicline or bupropion. The study end points were point-prevalence abstinence rates (1)for all subjects, and (2)associated with various treatment modalities, at the final SCC review, 6- and 12-month follow-up.

The point-prevalence abstinence rates for all patients at completion of SCC review, 6- and 12-month follow-up were 19.8%, 23.8% (p=0.033), and 25.4% (p=0.009), respectively. Abstinence rates between 6- and 12-month follow-up were not statistically different. A significant association between abstinence rates and the use of pharmacotherapy was detected at 6-months’ follow-up (p=0.005), but not at SCC review completion or 12-months’ follow-up (p>0.05). Abstinence rates were highest at 6- and 12-month with use of varenicline (37.4% and 34.3%, respectively) followed by combination NRT (21.7% and 26.1%). Furthermore, patients who had received only smoking cessation counselling had abstinence rates of 20.7% and 26.0% at 6- and 12-month follow-up.

Patient participation in a pharmacist-managed SCC was associated with significantly improved abstinence rates at 6- and 12-months following programme completion. The use of pharmacotherapy was significantly associated with overall abstinence rates at 6-months’ follow-up with varenicline appearing as the most effective smoking cessation aid.

Epidemiology & Disease Control Division, Ministry of Health, Singapore. National Health Survey 2010 – Singapore [Internet]. p31-36 Available from: (accessed August 2014).
American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014. Available from: (accessed Sept 2014).
World Health Organization. Media centre: Tobacco – Fact sheet N˚339 [Internet]. Available from: (accessed August 2014).
Epidemiology & Disease Control Division, Ministry of Health, Singapore. National Health Surveillance Survey 2007 – Singapore [Internet]. p15-22 Available from: (accessed Sept 2014).
Dent LA, Harris KJ, Noonan CW. Tobacco interventions delivered by pharmacists: A summary and systematic review. Pharmacotherapy. 2007;27(7):1040-51. doi: 10.1592/phco.27.7.1040
Tonnesen P. Smoking cessation: How compelling is the evidence? A review. Health Policy. 2009;91 Suppl 1:S15-25. doi: 10.1016/s0168-8510(09)70004-1
Ng YYY, Gwee XL. Effectiveness of an outpatient pharmacist-managed smoking cessation clinic in a Singapore hospital. Poster presented at: World Tobacco Conference 2012; Singapore.
Zow HC, Hsu AAL, Eng PCT. Smoking cessation programme: the Singapore General Hospital experience. Singapore Med J. 2004;45(9):430-4.
Kennedy DT, Giles JT, Chang ZG, Small RE, Edwards JH. Results of a smoking cessation clinic in community practice. J Am Pharm Assoc. 2002;42(1):51-6. doi: 10.1331/108658002763538071
Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacy. Addiction. 2001;96(2):325-31. doi: 10.1080/09652140020021062
Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Taylor Hays J, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers. JAMA. 2014;311(2):155-63. doi: 10.1001/jama.2013.283185.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-91. doi: 10.1056/NEJM199903043400903.
Zillich AJ, Ryan M, Adams A, Yeager B, Farris K. Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life. Pharmacotherapy. 2002;22(6):759-65. doi: 10.1592/phco.22.9.759.34073.
Roth MT, Westman EC. Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. Pharmacotherapy. 2001;21(5):636-41. doi:10.1592/phco.21.6.636.34548.
Koegelenberg CFN, Noor F, Bateman ED, van Zyl-Smith RN, Bruning A, O’Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation. JAMA. 2014;312(2):155-61. doi: 10.1001/jama.2014.7195.
Philbrick AM, Newkirk EN, Farris KB, McDanel DL, Horner KE. Effect of a pharmacist managed smoking cessation clinic on quit rates. Pharmacy Practice (Internet) 2009 Jul-Sep;7(3):150-6. PMCID: PMC4139046.
Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S Department of Health and Human Services. Public Health Service. May 2008. PMID: 18807274.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an 42 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. JAMA. 2006;296(1):56-63. doi:10.1001/jama.296.1.56.
Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179(2):135-44. doi: 10.1503/cmaj.070256.
Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313(7):687-94. doi: 10.1001/jama.2015.280.
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation (Review). Cochrane Database Syst Rev. 2004;(3):CD000146. doi: 10.1002/14651858.CD000146.pub2
Ho KS, Choi BWC, Chan HCH, Ching KW. Evaluation of biological, psychosocial, and interventional predictors for success of a smoking cessation programme in Hong Kong. Hong Kong Med J. 2016;22(2):158-64. doi: 10.12809/hkmj154549.
Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014;171(11):1199-205. doi: 10.1176/appi.ajp.2014.13050595.
Hong A, Elrashidi MY, Schroeder DR, Ebbert JO. Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. J Subst Abuse Treat. 2015;52:78-81. doi: 10.1016/j.jsat.2014.11.010.
Vogeler T, McClain C, Evoy KE. Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016;42(2):129-39. doi: 10.3109/00952990.2015.1117480.
Shiltz D, Paniagua A, Hastings JE. A retrospective comparison of varenicline monotherapy versus the combination of varenicline and bupropion or bupropion and nicotine patches in a VA tobacco cessation clinic. Journal of Smoking Cessation. 2011;6(1):65-73. doi: 10.1375/jsc.6.1.65.
Determinants of smoking cessation and abstinence in a Russian smoking-cessation center
Vladimir Levshin, Nina Slepchenko
Tobacco Prevention & Cessation
Journals System - logo
Scroll to top